DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4gwczh/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- 3M Drug Delivery Systems
- Adamis Pharmaceuticals Corporation
- ALK-Abello A/S
- AnaptysBio, Inc.
- Axikin Pharmaceuticals, Inc.
- BioTech Tools s.a.
- ELORAC, Inc.
- FAES Farma SA
- Fountain Biopharma Inc.
- GenMont Biotech Inc.
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals Ltd.
- GlycoMar Limited
- HAL Allergy BV
- Hanmi Pharmaceuticals, Co. Ltd.
- Hisamitsu Pharmaceutical Co., Inc.
- Johnson & Johnson
- Laboratorios LETI S.L.
- Ligand Pharmaceuticals, Inc.
- Marinomed Biotechnologie GmbH
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corporation
- Nektar Therapeutics
- NeoPharm Co., Ltd.
- Novartis AG
- Nuvo Research Inc.
- Ono Pharmaceutical Co., Ltd.
- Oxagen Limited
- Panmira Pharmaceuticals, LLC.
- Pfizer Inc.
For more information visit http://www.researchandmarkets.com/research/4gwczh/allergic_rhinitis